Bladder Cancer VL

Plasmacytoid Variant Bladder Cancer: Aggressive Disease Requiring Multimodal Therapy - Akshay Sood

Details
Ashish Kamat converses with Akshay Sood about the challenging diagnosis and management of non-metastatic plasmacytoid bladder cancer. Dr. Sood elaborates on his comprehensive study published in the Journal of Urology. He highlights the rarity and lethal nature of the plasmacytoid variant, which represents approximately 1% of muscle-invasive bladder cancers. Through a retrospective analysis of 56 p...

Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore

Details
Sam Chang converses with Neal Shore about the KEYNOTE-676 trial, focusing on combining pembrolizumab with BCG for high-risk NMIBC patients previously treated with BCG. This study aims to explore the potential synergy between two immunotherapeutic agents, leveraging pembrolizumab's success in MIBC to improve outcomes in NMIBC. With enrollment progressing well, the trial signals a collaborative futu...

Intravesical Erdafitinib (TAR-210) Demonstrates High Response Rates in NMIBC With Reduced Toxicity - Roger Li

Details
Sam Chang engages with Roger Li to delve into the TAR-210 study, focusing on bladder-based intravesical therapy targeting FGFR3 in non-muscle invasive bladder cancer (NMIBC) patients. Dr. Li shares insights from the multi-site international study, highlighting the efficacy of Erdafitinib, particularly in patients with FGFR alterations. Despite the challenges with oral Erdafitinib's toxicity, the i...

Genetic Overlap Discovered Between Cancerous and Non-Cancerous Bladder Tissue in Small Study - Roger Li

Details
Sam Chang and Roger Li delve into a study examining genetic profiles in non-muscle invasive bladder cancer and adjacent benign bladder tissue. Conducted on a cohort of nine patients, the study leveraged whole exome sequencing to explore mutations in both cancerous and non-cancerous tissue samples, uncovering a significant mutation overlap yet a lower mutation count in benign tissues. This investig...

ANTICIPATE II Trial: APL-1202 and Tislelizumab for Neoadjuvant Bladder Cancer Treatment - Matthew Galsky

Details
Sam Chang converses with Matthew Galsky about the ANTICIPATE II trial, examining the combination of APL-1202 (nitroxoline salt) and tislelizumab in treating muscle-invasive bladder cancer. Dr. Galsky discusses APL-1202's journey from an antibiotic with noted anti-cancer properties to a promising cancer treatment due to its immunogenic cell death induction and potential synergy with PD-1 inhibitors...

Comprehensive Genetic Profiling May Optimize Targeted Therapy Selection for FGFR3-Mutated Urothelial Carcinoma Patients - Michael Basin

Details
Michael Basin presents an analysis on FGFR alterations and the genomic landscape differences between upper and lower tract urothelial carcinoma. Utilizing data from the extensive Foundation Medicine database, which includes around 10,000 bladder cancer patients, Dr. Basin's study focuses on the subset with FGFR mutations. The research reveals that lower tract tumors possess more genomic co-drivers...

The Economic Impact of Cystectomy vs Trimodal Bladder Therapy - Stephen Williams

Details
Zachary Klaassen and Stephen Williams delve into the economic and treatment implications of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Dr. Williams, with a collaborative team spanning medical oncology to economic experts, has spent over a decade exploring these treatment pathways, revealing significant cost differences and outcomes through extensive research, in...

BCG Shortage: What’s on the Horizon to Replace? - Joshua Meeks

Details
Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability. The d...

PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson

Details
Ashish Kamat and Mark Tyson discuss the currently enrolling PIVOT-006 study. Dr. Tyson discusses cretostimogene grenadenorepvec, a conditionally replicating oncolytic adenovirus designed for cancer cell destruction and immunotherapeutic effects. Highlighting four pivotal studies demonstrating the agent's efficacy, especially in BCG unresponsive populations, Dr. Tyson outlines the development of in...

Establishing Nadofaragene Firadenovec in a Large Urology Practice - Daniel Canter

Details
Ashish Kamat and Daniel Canter discuss the role of nadofaragene firadenovec in the treatment of non muscle-invasive bladder cancer. Dr. Canter, drawing from his firsthand experience in Phase 1, 2, and 3 trials, highlights the therapy's tolerability and its efficacy, particularly noting its superior administration schedule compared to BCG. With a focus on real-world application, they explore the si...